2015 American Transplant Congress
Pharmacokinetics of Mycophenolic Acid (MPA) in Elderly Compared to Young Recipients in the First Year After Renal Transplantation. Data from the NEverOLd Trial
Elderly (≥60years) recipients are nowadays receiving renal transplants more frequently. The pharmacokinetics studies (PK) of immunosuppressive drugs in healthy volunteers, rarely, if ever, include old…2015 American Transplant Congress
Preliminary Results of a Novel Induction Regimen Using Anti-Thymocyte Globulin (Rabbit) (rATG) Plus Basiliximab in a Pediatric Patient Population Undergoing Kidney Transplantation
Purpose: We report the outcomes from single center experience with the novel induction regimen using rATG (3 mg/kg) in divided doses given on operative day…2015 American Transplant Congress
Favorable Long-Term Outcome of Late-Onset CMV Disease in D+R- Kidney Transplant Recipients Treated With Universal Prophylaxis
Based on last international guidelines, both universal prophylaxis and preemptive strategies are viable approaches for the prevention of cytomegalovirus (CMV) disease after organ transplantation. Universal…2015 American Transplant Congress
Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of Graft Failure and Mortality Among Kidney Transplant Recipients
Purpose: Graft loss and death are generally late events after kidney transplantation, and trials designed to assess the impact of interventions on these outcomes are…2015 American Transplant Congress
Should Only Active Candidates Define the EPTS Top 20% in the New Kidney Allocation System (KAS)?
1UNOS, Richmond, VA; 2Univ Hosp Case Med Ctr, Cleveland, OH; 3Yale, New Haven, CT.
Background: The 20% of kidney candidates with the highest Estimated Post-Transplant Survival (EPTS) receive priority for a high longevity kidney in the Organ Procurement and…2015 American Transplant Congress
Immunoglobulin G Donor-Specific Anti-HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury
Experimental and clinical data suggest that antibodies have different pathogenicities according to their IgG subclasses. We investigated the association between IgG subclasses of circulating anti-HLA…2015 American Transplant Congress
Extended Analysis of Tocilizumab (anti-IL-6R) + Intravenous Immunoglobulin (IVIG) as Desensitization (DES) Agents for Reduction of Donor Specific Antibodies (DSA) in Patients Resistant to DES With IVIG + Rituximab
Kidney Transplant, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: IVIG+rituximab is an acceptable approach for DES with good outcomes. Despite this, ∼30% of patients fail DES, thus other approaches are needed. Options include…2015 American Transplant Congress
Does Ureteric Stent Avoid Urological Complications After Renal Transplantation? A Retrospective Study of 10 Years Experience
Divison of Urology, Renal Transplantation Unit, University of São Paulo, São Paulo, SP, Brazil.
PURPOSE: Urinary leakage and ureteral stenosis are the most common surgical complications after kidney transplantation and are associated with significant morbidity, mortality and prolonged hospital…2015 American Transplant Congress
Risk Stratification in Tailoring Induction Therapy in Kidney Transplant Recipients(KTR): Is It Cost-Effective?
Transplant, Univ. of Utah, Salt Lake City, UT.
Intro: Selecting induction therapy based on immunologic risk in KTR has gained popularity but there has yet to be a study evaluating the cost beyond…2015 American Transplant Congress
Evaluation of Donor-Specific Antibodies Through 7 Years With Belatacept in BENEFIT and BENEFIT-EXT
1Emory University, Atlanta; 2Bristol-Myers Squibb, Lawrenceville.
Purpose: The development of donor-specific antibody (DSA) is linked to an increased risk of antibody-mediated rejection and graft failure. The 3 year intent-to-treat results from…
- « Previous Page
- 1
- …
- 504
- 505
- 506
- 507
- 508
- …
- 531
- Next Page »